Additional file 1: of High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

Figure S1. Kaplan-Meier plots of prostate specific antigen (PSA) recurrence after radical prostatectomy and negative or strong BCAR1 staining in subsets of all cancers defined by (a) classical Gleason score, (b-h) quantitative Gleason score defined by the percentage of Gleason 4 grade and (i-j) by the tertiary Gleason 5 grade. Figure S2. Kaplan-Meier plots of prostate specific antigen (PSA) recurrence after radical prostatectomy and BCAR1 staining in subsets of ERG negative cancers defined by (a) classical and (b-h) quantitative Gleason score, defined by the percentage of Gleason 4 grade and (i-j) by the tertiary Gleason 5 grade. Figure S3. Correlation of BCAR1 staining and androgen receptor (AR) staining in all cancers, Figure S4. Kaplan-Meier plot of prostate specific antigen (PSA) recurrence after radical prostatectomy and clinical stage in all cancers, Figure S5. Kaplan-Meier plot of prostate specific antigen (PSA) recurrence after radical prostatectomy and Gleason score at biopsy in all cancers, Table S1. Pathological and clinical data of the arrayed prostate cancer, Table S2. Association between BCAR1 staining and prostate cancer clinical characteristics in ERG–fusion negative and positive subsets, Table S3. Association between BCRA1 expression and Ki67-labeling index depending on ERG-fusion status in different Gleason scores. (DOC 5580 kb)